Introduction {#sec1_1}
============

Punctate inner choroidopathy (PIC) \[[@B1]\], an idiopathic primary choriocapillaritis, affects especially young myopic women \[[@B2]\]. Multiple yellowish white dots (100-300 µm) can aggregate in the inner choroid or retinal pigment epithelial layer, resulting in exudative retinal detachment \[[@B1],[@B3]\]. Choroidal neovascularization (CNV) secondary to PIC is the most vision-impairing complication next to subretinal fibrosis \[[@B2],[@B4]\]. Due to CNV maculopathy, reduced visual acuity, loss of central visual field and photopsia occur \[[@B1]\]. Clinical diagnosis is based on funduscopy, angiography with fluorescein (FA) or indocyanine green (ICGA) and spectral-domain optical coherence tomography (SD-OCT). Additionally autofluorescence images can provide further information due to autofluorescent spots in active and hypofluorescent spots in scar regions \[[@B5]\].

We report about a young myopic woman with unilateral CNV associated with PIC. The clinical features, diagnostic procedure and follow-up are presented.

Case Report {#sec1_2}
===========

A 29-year-old woman was referred to our Department of Ophthalmology with impaired visual acuity, photopsia and a central scotoma at her right eye (RE) for 2 weeks. Neither operation nor laser surgery was done before, and no additional ocular or systemic diseases were known. Best corrected visual acuity (BCVA) was 0.3 (RE, −8.50 sph) and 1.0 at the left eye (LE, −6.50 sph). Intraocular pressure was normal. Funduscopy of RE showed 'vitreoretinal glitter' (*Glitzerbeete*) at the inferior part of the retina and multiple yellowish dots at the posterior pole without other signs of inflammation (fig. [1a](#F1){ref-type="fig"}), being hyperfluorescent (early phase) with a diffuse leak (late phase) in FA (fig. [2a](#F2){ref-type="fig"}). SD-OCT showed a slightly elevated retinal pigment epithelial layer (fig. [1b](#F1){ref-type="fig"}). Blood chemistry and count (except decreased basophil granulocytes) as well as immunoglobulins (IgM and IgG) for *Borrelia burgdorferi*, *Treponema pallidum* (TPHA) were normal. Starting with an anti-inflammatory therapy (prednisolone acetate eye drops) in our policlinic resulted in a discrete improvement of BCVA (0.5 RE) after already 4 days until 0.8 BCVA after 2 months. As paracentral scotoma occurred at that point of follow-up, further FA revealed a classic CNV. ICGA showed a hypofluorescent signal (fig. [2b](#F2){ref-type="fig"}). Because of this CNV, an intravitreal injection of anti-vascular endothelial growth factor (VEGF, bevacizumab, 1 mg/0.05 ml) was administered, stabilizing BCVA at 0.8-1.0 in the following months. Local antiglaucomatous drops were added as intraocular pressure increased (30 mm Hg). Three months after the first anti-VEGF injection, the patient was referred again because of spreading of central scotoma (RE: BCVA 0.8). FA revealed a new activity of the classic CNV. Now a systemic anti-inflammatory therapy with prednisone (120 mg) and azathioprine (2 mg/kg body weight/day) was started. Two more intravitreal injections of bevacizumab (1 mg/0.05 ml, BCVA at injection 2: 0.5; BCVA at injection 3: 0.8; RE) were administered. Under this therapy, BCVA was stabilized at 0.8 (RE) for 5 months. Afterwards BCVA decreased again (0.2) with recurrence of CNV and increased spreading in the central part of the fovea. On the patient\'s demand, no further intravitreal injection of anti-VEGF was done, but local and systemic therapy were continued. BCVA stabilized at 0.5 under azathioprine and tapered prednisone medication without CNV activity in SD-OCT.

Discussion {#sec1_3}
==========

CNV is a common complication in PIC disease. Rates of 69-75% were reported in the literature \[[@B5]\], yet treatment is still a challenge. Only few cases have been published reporting the use of local or systemic anti-inflammatory medications (e.g. corticosteroids, immunomodulators), argon laser photocoagulation, photodynamic therapy (PDT), retinal surgery of CNV or intravitreal anti-VEGF injections.

Systemic corticosteroids were applied successfully in the treatment of juxtafoveal (BCVA increase 1/10-6.7/10 \[[@B6]\]) and subfoveal CNV (average BCVA increase 6/18-6/12 \[[@B7]\]). The frequency of recurrent PIC can be reduced by immunomodulators like mycophenolate mofetil \[[@B8]\]. Laser photocoagulation is discussed controversially because of an increased risk of generating CNV, scare growth and the potential of reaching foveal structures \[[@B9]\]. Alternatively, PDT was shown to increase BCVA and stabilize CNV \[[@B10]\]. An increase in BCVA was also observed for the combination of PDT with systemic corticosteroids (mean: 8.6 letters, follow-up 12 months, number of PDT: 2 \[[@B11]\]) or with intravitreal triamcinolone (BCVA 0.52-0.20, follow-up 12 months \[[@B12]\]). Submacular surgery can be considered for subfoveal CNV, yet a 66.7% recurrence of CNV was reported \[[@B13]\]. No studies are available for surgical treatment of extrafoveal CNV at this moment. A further option in medical treatment offers the off-label application of anti-VEGF injections. Either bevacizumab (1.25 mg/0.05 ml \[[@B14]\]) or ranibizumab (0.5 mg/0.1 ml \[[@B15]\]) resulted in an improved BCVA (mean: 64--85 ETDRS letters, follow-up 87.2 weeks \[[@B15]\]).

In our patient, after resolution of the acute PIC inflammation, resulting in a rapid increase of BCVA from 0.3 to 0.8, a classic CNV decreased BCVA due to macula involvement. An intravitreal anti-VEGF injection (bevacizumab) was given, and BCVA increased up to 1.0. After 3 months, a recurrence of CNV occurred, systemic immunosuppression was intensified (prednisone and azathioprine), and two additionally bevacizumab injections were applied. BCVA increased again up to 0.8. A further recurrence of CNV after 5 months (BCVA 0.2) was treated without anti-VEGF injection (considering the patient\'s desire), but with continuation of local and systemic immunosuppression, resulting in a lasting improvement of BCVA (0.5) and stabilizing CNV in SD-OCT. It is not a matter of course that a combined therapy, as in the presented case, does always lead to this good visual outcome. Whether a combination of distinct therapeutic options, a single medical treatment or a simple 'wait and see' regime is the best therapy for PIC remains open, as PIC can also show a spontaneous resolution.

Conclusion {#sec1_4}
==========

Combined therapy of immunosuppression with intravitreal anti-VEGF injections should be considered as therapeutic strategy in the management of recurrent CNV associated with PIC.
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![Fundus photography and SD-OCT images of the right eye at the first visit (**a**, **b**). **a** Posterior pole with multiple yellowish dots. **b** SD-OCT image yielding a juxtafoveolar intraretinal edema as well as a slightly elevated retinal pigment epithelium.](cop-0006-0385-g01){#F1}

![Angiography with fluorescein (**a**) and indocyanine green (**b**) of the right eye. **a** Fluorescein angiography: circumscribed leakage increased in an area of the yellowish dots (late phase, 4:53 min). **b** Indocyanine green angiography: hypofluorescent signals corresponding to the hyperfluorescent angiographic ones (after 2:18 min).](cop-0006-0385-g02){#F2}
